TheraP

Prostate — In Follow-up

TheraP

Lutetium-177 PSMA radionuclide therapy (Lu-PSMA) is a new treatment for advanced prostate cancer. Lu-PSMA is a radioactive molecule that specifically attaches to cells with high amounts of PSMA on the surface of the cells. This allows the radioactivity to be delivered mainly to the prostate cancer cells wherever they have spread, while sparing most normal tissues. Previous small studies of Lu-PSMA showed promising activity in patients with advanced prostate cancer.

This randomised study will compare Lu-PSMA with a type of chemotherapy called cabazitaxel, which is the standard treatment for advanced prostate cancer when other treatments have stopped working. Half the participants will receive Lu-PSMA and half will receive cabazitaxel. This study will provide further information about the risks and benefits of Lu-PSMA compared with cabazitaxel in people with prostate cancer. We plan to enrol 200 participants in the study in Australia.

Further TheraP Information

If you think this trial might be right for you, please ask your doctor.

Trial Title

A randomised phase II trial of 177Lu-PSMA617 theranostic versus cabazitaxel in progressive metastatic castration resistant prostate cancer

Cancer Type

Prostate

Trial Status

In Follow-up

Protocol Number

ANZUP 1603

Trial Email

therap.study@sydney.edu.au

Co-ordinating centre

NHMRC Clinical Trials Centre

Study Chair

Professor Michael Hofman

Patient Population

Men with mCRPC suitable for cabazitaxel chemotherapy.

Recruitment Target

200 participants

Acknowledgements

TheraP is a partnership between ANZUP Cancer Trials Group and the Prostate Cancer Foundation of Australia (PCFA) with support from the Australian Nuclear Science and Technology Organisation (ANSTO), Endocyte, It’s a Bloke Thing, Movember and CAN4CANCER